2025-03-12 00:20:22
Latest Post
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Hexaware Inaugurates Global Business Headquarters in Jersey City
HCLTech among Ethisphere's 2025 World's Most Ethical Companies®
Ind-Swift Laboratories Ltd receives 'Best Employer Brand - Punjab 2025' by World HRD Congress
Stock Report
Gland Pharma Ltd consolidated Q2 FY24 PAT at Rs. 194.08 crores
Posted On : 2023-11-07 11:26:34( TIMEZONE : IST )
Gland Pharma Limited has reported Consolidated financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 1426.579 crores during the period ended September 30, 2023 as compared to Rs. 1246.235 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. 194.082 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. 194.102 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. 11.78 for the period ended September 30, 2023 as compared to Rs. 11.78 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 1426.579 crs | ₹1246.235 crs |  14.47% |
| Net Profit | ₹194.082 crs | ₹194.102 crs |  -0.01% |
| EPS | ₹11.78 | ₹11.78 |  0.00% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 1426.579 crores during the period ended September 30, 2023 as compared to Rs.1110.028 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.194.082 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.241.242 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.11.78 for the period ended September 30, 2023 as compared to Rs.14.65 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 1426.579 crs | ₹1110.028 crs | 28.52% |
| Net Profit | ₹194.082 crs | ₹241.242 crs | -19.55% |
| EPS | ₹11.78 | ₹14.65 | -19.59% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.2672.814 crores during the 6 Months period ended September 30, 2023 as compared to Rs.2041.317 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.388.184 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.470.411 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.23.56 for the 6 Months period ended September 30, 2023 as compared to Rs.28.57 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹2672.814 crs | ₹2041.317 crs | 30.94% |
| Net Profit | ₹388.184 crs | ₹470.411 crs | -17.48% |
| EPS | ₹23.56 | ₹28.57 | -17.54% |
Shares of Gland Pharma Limited was last trading in BSE at Rs. 1574.85 as compared to the previous close of Rs. 1511.50. The total number of shares traded during the day was 35478 in over 3419 trades.
The stock hit an intraday high of Rs. 1633.00 and intraday low of 1503.70. The net turnover during the day was Rs. 56051495.00.
